Afatinib, an EGFR inhibitor, decreases EMT and tumorigenesis of Huh-7 cells by regulating the ERK-VEGF/MMP9 signaling pathway

YAFEI CHEN, XIN CHEN, XIAOJUN DING and YINGWEI WANG

Department of Clinical Laboratory, Tiantai People's Hospital, Taizhou, Zhejiang 317200, P.R. China

Received July 2, 2018; Accepted April 24, 2019

DOI: 10.3892/mmr.2019.10562

Abstract. Transcatheter arterial embolization (TAE) therapy has been used in the treatment of inoperable hepatocellular carcinoma (HCC). However, tumor recurrence and metastasis are common in patients after TAE, and these processes may be caused by circulating tumor cells (CTCs). Epithelial-mesenchymal transition (EMT) serves important roles in CTCs, and abnormal expression and activation of epidermal growth factor receptor (EGFR) is common in cancer cells. Afatinib is an EGFR-tyrosine kinase inhibitor (TKI). The present study aimed to investigate the effects of afatinib on EMT and tumorigenesis in HCC cells. Western blot analysis suggested that afatinib was able to effectively suppress overactivation of EGFR. Moreover, the expression levels of EMT- and metastasis-associated genes were found to be modulated by afatinib through EGFR inhibition. In addition, Cell Counting Kit-8 and Transwell assays suggested that the viability, migration and invasion of HCC cells were inhibited by afatinib through EGFR inhibition. Furthermore, the activity of the ERK signaling pathway and the expression levels of vascular endothelial growth factor (VEGF) and matrix metalloproteinase 9 (MMP9) were decreased following treatment with afatinib in vitro. Collectively, the present results suggested that the inhibitory effects of afatinib on EMT and tumorigenesis may be associated with the ERK-VEGF/MMP9 signaling pathway. The present study provides new insights into understanding the mechanism underlying HCC and may facilitate the development of novel therapeutic strategies to treat HCC recurrence.

Introduction

Primary hepatocellular carcinoma (HCC) is a malignancy with high mortality rate, and it is common in developing countries (1). HCC is a leading cause of tumor-associated mortality in China, partly due to the high occurrence rate of chronic hepatitis B virus infection (2). Transcatheter arterial embolization (TAE) has been widely used for the treatment of inoperable hepatocellular carcinoma, and it has been shown to decrease the tumor volume with promising effects (3); however, tumor recurrence and metastasis are common after TAE (4,5), and these processes may be caused by circulating tumor cells (CTCs). CTCs have the ability to invade distant tissues and to survive in various microenvironmental contexts (6). The expression of epidermal growth factor receptor (EGFR), a transmembrane tyrosine kinase receptor (7), has been identified to have an important role in CTCs (6). EGFR is dysregulated in many types of cancer, including HCC (8). Although EGFR signaling was identified to be critical for HCC growth and metastasis, and a previous study identified that treatment with the EGFR inhibitor cetuximab could reduce HCC growth following TAE, the effects of other EGFR inhibitors, such as afatinib, and their possible regulatory mechanisms in HCC cells following TAE remain unknown (9,10). Afatinib, an EGFR-tyrosine kinase inhibitor (TKI), was previously identified to repress cancer cell growth by mitigating the activation of EGFR in tumor cells (11). A previous study reported that epithelial-mesenchymal transition (EMT) has a critical role in the shedding of CTCs from primary tumors into blood vessels, and EMT is an essential process in embryonic development and cancer progression (12). EMT is characterized by a loss of cell polarity, cell-cell adhesion, and increased migratory and invasive abilities, which facilitate the metastasis of cancer cells (13,14). E-cadherin and Vimentin are involved in the EMT process (15). In addition, metastasis-associated gene 1 (MTA1) (16,17) and T lymphoma invasion and metastasis inducing factor 1 (TIAM1) are responsible for cell migration and adhesion in tumorigenesis (18-20). Therefore, afatinib may be involved in preventing EMT in HCC following TAE. Vascular endothelial growth factor (VEGF) is a potent inducer of angiogenesis and was identified to be associated with tumor angiogenesis (21). Matrix metalloproteinase (MMPs) play critical roles in proteolytic degradation and in altering cell adhesion, cell migration and EMT during cancer-associated...
angiogenesis (22-24). ERK is a member of the mitogen-activated protein kinase (MAPK) signaling cascade (25), and was identified to be involved in multiple biological processes regulated by phosphorylation cascades, including gene expression, cell survival and cell migration (26-28). Therefore, the present study aimed to investigate the effects of afatinib on HCC after TAE and the potential mechanisms underlying its function. The present results suggested that afatinib was able to effectively suppress the overactivation of EGFR. Moreover, the expression levels of genes involved in proliferation, migration, invasion and EMT were decreased following treatment with afatinib through EGFR inhibition in HCC cells, and these effects may be associated with the ERK-VEGF/MMP signaling pathway. The present results may provide new insights into the mechanisms underlying the prevention of HCC recurrence after TAE.

Materials and methods

Tissue specimens. In total, 50 patients with HCC underwent TAE intervention therapy in Tiantai County People's Hospital between June 2014 and April 2016. The inclusion criteria were the following: i) All patients with HCC were diagnosed by histological analysis; ii) all patients underwent curative surgery with no presurgical treatment resulting in tissue necrosis; iii) all patients did not receive radiotherapy or chemotherapy before surgical intervention; and iv) no patient had concurrent presence of another liver carcinoma. Signed written informed consent was obtained from 42 patients for the use of their clinical tissues. Eight patients did not provide written informed consent and were thus excluded from the present study. The adjacent normal tissues were collected according to the Declaration of Helsinki. Paired tissues were divided into two groups. Sections were stored in 4% formaldehyde at -80°C for routine pathological diagnosis, whereas the other part was frozen by immersion into liquid nitrogen for routine pathological diagnosis, whereas the other part was frozen by immersion into liquid nitrogen for routine pathological diagnosis, whereas the other part was frozen by immersion into liquid nitrogen for routine pathological diagnosis, whereas the other part was frozen by immersion into liquid nitrogen. Subsequently, 1 µg RNA was reversely transcribed using the PrimeScript™ RT reagent Kit (Takara Bio Inc.), and stored at -80°C. Reverse transcription-quantitative PCR (RT-qPCR) and western blot analysis were performed to examine the tissues. The association between the expression level of EGFR and clinicopathological features is presented in Table I. The present study was approved by The Ethics Committee of Tiantai County People's Hospital.

Cell culture and treatment. Huh-7 cells were purchased from Thermo Fisher Scientific, Inc. The cells were maintained at 37°C in an incubator with 5% CO2, and cultured in DMEM (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) streptomycin and penicillin (CoWin Biosciences Co., Ltd.). Cells were plated in 6-well plates at a density of 1x10^5 cells/well and were starved overnight before treatment. On the following day, the cells were treated with 25 ng/ml recombinant human EGF (PeproTech, Inc.) for 6 h to mimic the overactivation of EGFR in HCC after TAE.

Cell transfection. Subsequently, the cells were transfected with small interfering RNAs (siRNAs). EGFR siRNA (si-EGFR) and scrambled siRNA (si-CTR) were purchased from Shanghai GenePharma Co., Ltd. In total, 0.25 µg siRNA was transfected into Huh-7 cells, using Lipofectamine 3000 (Invitrogen; Thermo Fisher Scientific, Inc.) as transfection reagent. 24 h after transfection, cells were used for following detection. Subsequently, 10 nmol afatinib (Selleck Chemicals) was added to 100 µl cell culture medium for 18 h at 37°C. Treatment with DMSO (0.1%) was used as the control.

Assessment of cell viability. After 18 h of treatment with afatinib, the cells were plated at a density of 1x10^5 cells/well in 96-well plates. Then, cell viability was detected using a Cell Cycle Kit-8 (CCK-8) according to the manufacturer's protocol (Beyotime Institute of Biotechnology). The CCK-8 solution was added and incubated at 37°C. After 4 h, the medium was removed and a microplate reader (Bio-Rad Laboratories, Inc.) was used for determining absorbance values at 450 nm.

Detection of migratory and invasive abilities of Huh-7 cells. Matrigel-coated Transwell inserts (Corning, Inc.) were used to measure the migratory and invasive abilities of cancer cells, as previously described (29). For the migration assay, the inserts were not coated with Matrigel. Cells were plated at a concentration of 2x10^5 cells/ml in the upper chamber and incubated for 24 h. Crystal violet (0.1%) was used for staining at 37°C for 20 min. The migrated or invaded cells were counted for 200 fold using a light microscope (Nikon Corporation; magnification, x200), and the averages were calculated.

RT-qPCR. The relative gene expression data were analyzed by RT-qPCR. Total RNA was extracted using RNeasy kit (Qiagen GmbH). Subsequently, 1 µg RNA was reversely transcribed to cDNA using High-capacity cDNA Reverse Transcription Kit (Applied Biosystems; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. The qPCR was performed using the ChamQ SYBR qPCR master mix (Vazyme) on a Bio-Rad CFX96 system. The thermocycling conditions were the following: Initial denaturation at 95°C for 15 sec, followed by 40 cycles of 95°C for 25 sec, 55°C for 25 sec and 72°C for 30 sec. RT-qPCR data were quantified using the 2^-ΔΔCT method (30). GAPDH was used as internal control gene. The sequences of the primers used in the present study are listed in Table II.

Western blotting. Total protein was extracted using RIPA buffer (Boster Biological Technology) and 1 mmol/l PMSF and separated by SDS-PAGE on 12% gels. Next, the proteins were transferred to PVDF membranes (EMD Millipore). Subsequently, 2% BSA (Beijing Solarbio Science & Technology Co., Ltd.) was added to block nonspecific binding. The PVDF membranes were incubated overnight at 4°C with primary antibodies (all from Cell Signaling Technology, Inc.) against phosphorylated (p)-EGFR (cat. no. 4407; 1:1,000), EGFR (cat. no. 3197; 1:000), MMP9 (cat. no. 3852; 1:000), p-ERK (cat. no. 9101; 1:000), ERK (cat. no. 9102; 1:000), VEGF (cat. no. 2463; 1:000), E-cadherin (cat. no. 3195; 1:000), Vimentin (cat. no. 5741; 1:000), TIMP1 (cat. no. 63647; 1:000), MTa1 (cat. no. 5646; 1:000) and GAPDH (cat. no. 2118; 1:2,000). After being washed with PBS, the membranes were incubated with a horseradish peroxidase-labeled secondary antibody (cat. no. 7074; 1:5,000; Cell Signaling Technology, Inc.). The bands were visualized using an ECL kit (Pierce; Thermo Fisher Scientific, Inc.).
Fisher Scientific, Inc.). Digital images of immunoreactive bands were analyzed using the Bio-Rad ChemiDoc XRS+ System with Image Lab Software (version 1708265; Bio-Rad Laboratories, Inc.).

Statistical analysis. SPSS 22.0 (IBM Corp.) and GraphPad Prism 6 software (GraphPad Software, Inc.) were used for statistical analysis. Data are presented as the mean ± SD. The \( \chi^2 \) test was used to analyze the association between the expression level of EGFR and various clinical features or between the expression levels of EGFR and E-cadherin. One-way ANOVA followed by Dunnett’s post-hoc test was used to compare multiple groups. \( P<0.05 \) was considered to indicate a statistically significant difference.

Results

Expression level of EGFR in HCC after TAE. The mRNA and protein expression level of EGFR in HCC tissues was investigated using RT-qPCR and western blot analysis, respectively. The results suggested that EGFR was upregulated in HCC tissues and increased following TAE compared with the control group (Fig. 1). The association between the expression level of EGFR and various clinicopathological features was also examined (Table I). The expression level of EGFR was significantly associated with intravascular tumors and the retraction/lesion of the liver capsule, but not with gender, age and tumor diameter. In addition, the expression level of E-cadherin was significantly reduced in HCC tissues, in

Table I. Association between EGFR expression and various clinicopathological features.

| Clinicopathological features | n    | Positive, n (%) | Negative, n (%) | P-value |
|-----------------------------|------|----------------|----------------|---------|
| Sex                         |      |                |                |         |
| Male                        | 32   | 11 (34.4)      | 21 (65.6)      | 0.798   |
| Female                      | 10   | 3 (30.0)       | 7 (70.0)       |         |
| Age, years                  |      |                |                |         |
| \( \leq 50 \)               | 15   | 7 (46.7)       | 8 (53.3)       | 0.172   |
| \( >50 \)                   | 27   | 7 (25.9)       | 20 (74.1)      |         |
| Histology differentiation   |      |                |                | 0.127   |
| High                        | 8    | 5 (62.5)       | 3 (37.5)       |         |
| Moderate                    | 19   | 7 (36.8)       | 12 (63.2)      |         |
| Low                         | 15   | 2 (20.0)       | 13 (80.0)      |         |
| Liver cirrhosis             |      |                |                | 0.35    |
| Yes                         | 36   | 11 (30.6)      | 25 (69.4)      |         |
| No                          | 6    | 3 (50.0)       | 3 (50.0)       |         |
| \( \alpha \)-fetoprotein    |      |                |                | 0.469   |
| \( \leq 400 \)              | 30   | 11 (36.7)      | 19 (63.3)      |         |
| \( >400 \)                  | 12   | 3 (25.0)       | 9 (75.0)       |         |
| Tumor diameter, cm          |      |                |                | 0.116   |
| \( \leq 5 \)                | 26   | 11 (42.3)      | 15 (57.7)      |         |
| \( >5 \)                    | 16   | 3 (18.8)       | 13 (81.3)      |         |
| TNM stage                   |      |                |                | 0.075   |
| I/II                        | 25   | 11 (44.0)      | 14 (56.0)      |         |
| III/IV                      | 17   | 3 (17.6)       | 14 (82.4)      |         |
| Intravascular tumor thrombus|      |                |                | 0.028*  |
| Yes                         | 19   | 3 (15.8)       | 16 (84.2)      |         |
| No                          | 23   | 11 (47.8)      | 12 (52.2)      |         |
| Portal vein tumor thrombus  |      |                |                | 0.736   |
| Yes                         | 5    | 2 (40.0)       | 3 (60.0)       |         |
| No                          | 37   | 12 (32.4)      | 25 (67.6)      |         |
| Involving the liver capsule |      |                |                | 0.005*  |
| Yes                         | 32   | 7 (21.9)       | 25 (78.1)      |         |
| No                          | 10   | 7 (70.0)       | 3 (30.0)       |         |

\*\( P<0.05 \). EGFR, epidermal growth factor receptor; TNM, tumor, node and metastasis.
Table II. Reverse transcription-quantitative PCR primers.

| Gene symbol | Primer sequences (5'-3') |
|-------------|-------------------------|
| EGFR        | F: GCGTACTCTTTGTCAATTCAGG |
|             | R: TACATAGGAAGCCACAGTTG |
| E-cadherin  | F: TCACATCTACACTGGCCAGAG |
|             | R: AGTGTCCCTGTCCAGTGGC |
| MMP9        | F: GCCGCTCCCTCCTACCTTC |
|             | R: ATAGGGTGACATGAGCCGCTTC |
| VEGF        | F: TGGTCTGGTGGGGGTAC |
|             | R: GGTCTATGGGCTGTCTTTC |
| Vimentin    | F: GAGAGGAGGCAGAAACACC |
|             | R: TCCCTGAATCCTGGCGGC |
| MTA1        | F: ACGACAGCAATCTGCAAGC |
|             | R: GCCTTGAGATGCTGTAGA |
| TIAM1       | F: ACTGCTCTCTGAGTGCC |
|             | R: GGTGATGGGCTGAGTTG |
| GAPDH       | F: CAGACCTATGCCATCAGT |
|             | R: ATTCGCTTCTGGAGATGG |

EGFR, epidermal growth factor receptor; F, forward; R, reverse; MMP, matrix metalloproteinase; VEGF, vascular endothelial growth factor; MTA1, metastasis associated 1; TIAM1, T cell lymphoma invasion and metastasis 1.

Table III. Association between the expression levels of EGFR and E-cadherin.

| EGFR expression | E-cadherin expression | n | P-value |
|-----------------|-----------------------|---|--------|
| - (46.7%)       | + (53.3%)             | 15| 0.206  |
| + (66.7%)       | (33.3%)               | 27|        |

EGFR, epidermal growth factor receptor.

particular after TAE (Fig. 1). Although the expression levels of EGFR and E-cadherin were not significantly associated with each other, 18 patients (66.7%) exhibited positive expression of EGFR and negative expression of E-cadherin (Table III). Sample exhibiting higher levels than the control group were considered positive, whereas samples with lower levels were considered negative.

Afatinib modulates the expression levels of EMT- and metastasis-associated genes in HCC cells. EMT is involved in the migration of tumor cells, thus increasing the tumor metastatic ability (31). RT-qPCR and western blot analysis showed that knockdown of EGFR expression by siRNA decreased the protein expression level ratio of p-EGFR/EGFR. Moreover, atafinib could effectively suppress the phosphorylation of EGFR; whereas the knockdown of EGFR expression by siRNA decreased the ratio of p-EGFR/EGFR. Moreover, atafinib could effectively decrease the ratio of p-EGFR/EGFR (Fig. 2A-C). Additionally, the mRNA and protein expression levels of EMT- and metastasis-associated genes were examined by RT-qPCR and western blot, respectively. The expression levels of E-cadherin and TIAM1, which are negative regulators of EMT (32,33), were increased following EGFR knockdown or atafinib-mediated inhibition of EGFR. However, the expression levels of Vimentin and MTA1, which are positive regulators of EMT (34,35), were decreased in EGFR knockdown group or the atafinib group (Fig. 2D-F).

Afatinib inhibits viability, migration and invasion of HCC cells. The effects of atafinib on HCC tumorigenesis were investigated in vitro. The CCK-8 results suggested that cell viability was reduced (Fig. 3A) in the EGFR-TKI group. Moreover, the Transwell assays suggested that the migratory and invasive abilities of HCC cells were significantly decreased following treatment with atafinib (Fig. 3B-E). Collectively, the present results suggested that atafinib could inhibit the viability, migration and invasion of HCC cells through EGFR inhibition.

Activity of the ERK-VEGF/MMP9 signaling pathway is decreased by atafinib through EGFR inhibition. To investigate the molecular mechanisms underlying atafinib function, the activity of ERK and the expression levels of VEGF and MMP9 were investigated following treatment with atafinib. RT-qPCR and western blot analysis results suggested that the expression levels of VEGF and MMP9 were decreased by atafinib through EGFR inhibition (Fig. 4A and B). Moreover, the phosphorylation level of ERK was significantly decreased after treatment with atafinib through EGFR inhibition, and the ratio of p-ERK/ERK was significantly decreased after treatment with atafinib through EGFR inhibition (Fig. 4C and D). The present results suggested that atafinib decreased the activity of the ERK-VEGF/MMP9 signaling pathway in vitro.

Discussion

HCC is a type of malignant cancer with high incidence rates worldwide (1). TAE is an effective palliative treatment for inoperable HCC. Nevertheless, a high incidence of HCC recurrence and metastasis was reported after TAE (5). Multiple intracellular signals are altered in HCC cells following TAE, leading to an increased number of CTCs, thus promoting metastasis and tumor recurrence (4,5). As one of the most widely investigated receptor tyrosine kinase families, EGFRs serve important roles in signal transduction and oncogenesis (36). Previous studies reported that EGFR is overactivated or mutated in HCC; Ikeda et al (40) performed next-generation sequencing to investigate circulating tumor DNA, and found that 14% of patients with HCC presents an increased number of copies of EGFR. EGFR was activated in HCC cells (41). In addition, Panvichian et al (42) demonstrated that EGFR overexpression and mutations in the EGFR gene are present in HCC. EMT contributes to the growth and metastasis of cancer cells in the
VEGF has an important role in the proliferation and differentiation of endothelial cells (21). In addition, MMPs serve key roles in the degradation of basement membrane collagen and extracellular matrix (43). Interestingly, afatinib, a TKI able to suppress the activity of EGFR, can interact with the ATP-binding site of EGFR, blocking its enzymatic activity (44). In a previous study, EGFRWT and EGFRl858r/T790M kinase inhibition assays identified that afatinib has significant inhibitory activities, and its IC50 values, tested in a HepG2, MCF-7 and PC-3 cell lines, are in the nanomolar range (45). Moreover, afatinib was reported to have inhibitory effects on non-small-cell lung cancer (NSCLC) and has been approved for the therapy of metastatic NSCLC by the Food and Drug Administration (45,46). Therefore, the present study aimed to investigate the effects of afatinib on HCC and its underlying molecular mechanism.

Fang et al (47), reported that possible mechanisms underlying the metastatic potential of HCC cells following TAE are...
the acquisition of EMT features and the increased number of CTCs. The present study not only examined the expression levels of genes involved in the mechanism underlying HCC metastasis, but also suggested a possible EGFR-targeted therapeutic strategy.
was not significantly associated with the expression level of E-cadherin; however, 18 patients (66.7%) were EGFR-positive and E-cadherin-negative. A higher number of samples are required to confirm the association between the expression levels of these two genes. The present results suggested that EGFR could be used as a target for the prevention of EMT in HCC after TAE. In the present study, the effects of afatinib on the activity of EGFR signaling were investigated. Additionally, the expression levels of E-cadherin and Vimentin, two genes associated with EMT, increased and decreased following afatinib-mediated EGFR inhibition, respectively. Moreover, the expression levels of the metastasis-associated genes MTA1 and TIA1 were decreased and increased in the EGFR-TKI group, respectively. Wang et al (52) suggested that silencing EGFR or inhibiting the phosphorylation of molecules downstream of the EGFR pathway could inhibit EMT and metastasis in HCC. Deng et al (53) reported that reducing the activity of HER2, a member of the EGFR family, can decrease the promotion of EMT by increasing the expression level of MTA1 in HCC both in vitro and in vivo, suggesting that the EGFR-MTA1-EMT1 pathway may be context-specific. In addition, the acquisition of EMT features was observed in lung cancer cell lines, and is associated with an increased resistance to afatinib (54). Nevertheless, EMT-associated resistance to afatinib in the treatment of HCC requires further validation in clinical studies. A previous study reported that the effects of combined treatment with bufalin and afatinib is associated with the inhibition of EMT in lung cancer cells (55). Therefore, combined treatments and conversion therapies may be used in the treatment of HCC. In addition, CCK-8 and Transwell assays were performed to investigate the effects of afatinib on tumorigenesis. The present results suggested that afatinib decreased the proliferation, migration and invasion of HCC cells through EGFR inhibition. The inhibitory effect of afatinib on the migration and metastasis of HCC cells was in accordance with a previous study describing the effects of afatinib on NSCLC (46). In the present study, the molecular mechanism of afatinib was investigated in HCC cells.

The MAPK/ERK pathway is involved in numerous biological events, including cancer progression (26,28,56). In the present study, the protein expression level of p-ERK was identified to be reduced by afatinib in vitro. The present results suggested that afatinib may exert its inhibitory effect on tumorigenesis by inactivating the ERK signaling pathway. The present findings are in line with a previous study that showed induction of apoptosis in Eca109 cells following knockdown of ERK2 (8). Nevertheless, a previous study reported that the effect of the ERK signaling pathway depends on the cellular context and the crosstalk with other signaling pathways (46). In addition, VEGF and MMPs are responsible for tumor angiogenesis, growth and metastasis (57-59). Zhang et al (60) investigated the effects of metformin in combination with curcumin on the growth and progression of HCC, and the downregulation of the expression levels of MMP2/9, VEGF and VEGF receptor-2 were identified to be associated with the suppression of EGFR signaling. This previous study is in line with the present study, which suggested that the expression levels of VEGF and MMP9 were decreased by afatinib through EGFR inhibition in HCC cells. Previous studies demonstrated that the VEGF signaling pathway promotes the activation of MMPs in endothelial cells (57,58,61). However, the present study did not investigate whether VEGF regulated MMP9, which were previously shown to be associated (62). Additionally, previous studies showed that the MAPK/ERK pathway is downstream of the VEGF signaling pathway (63,64); in contrast, a previous study showed that the upregulation of VEGF is dependent on ERK activation (65). Therefore, ERK may regulate VEGF signaling in a positive feedback mechanism. Therefore, examining the hierarchy between ERK and VEGF could improve the understanding of the molecular mechanism investigated in the present study. However, the present findings may increase the understanding of HCC, facilitating the development of novel treatments. The present study identified certain limitations, including the lack of clinical studies. In addition, to examine the effects of agonists of the ERK signaling pathway may validate the molecular mechanism identified in the present study.

Collectively, the present study identified that afatinib could not only effectively suppress the proliferation, migration and invasion of HCC cells, but also regulated the expression levels of EMT- and metastasis-associated genes through EGFR inhibition. Furthermore, the inhibitory effects of afatinib on tumorigenesis were identified to be associated with the ERK-VEGF/MMP9 signaling pathway. The present findings may facilitate the development of a novel therapeutic strategy for the recurrence of HCC.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

YC conceived and designed the present study. XC and XD performed the experiments. YW analyzed, collected and interpreted the data.

Ethics approval and consent to participate

The present study was approved by The Ethics Committee of Tiantai County People's Hospital. Written informed consent was obtained from 42 patients for the use of their clinical tissues.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.
References

1. Burkhardt RA, Ronneklev-Kelly SM and Pawlik TM: Personalized therapy in hepatocellular carcinoma: Molecular markers of prognosis and therapeutic response. Surg Oncol 26: 201-212, 2017.

2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.

3. Nagao E, Hiraakawa M, Soeda H, Tsuruta S, Sakai H and Honda H: Transectable arterial embolization for chest wall metastasis of hepatocellular carcinoma. World J Surg 5: 45-48, 2013.

4. Wang R, Zhao N, Li S, Fang JH, Chen MX, Yang J, Jia WH, Yuan Y and Zhuang SM: MicroRNA-195 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting the expression of VEGF, VAV2, and CDC42. Hepatology 58: 652-653, 2013.

5. Germano D and Daniele B: TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis. Hepatobiliary Surg Nutr 3: 166-167, 2014.

6. Serrano MJ, Alvarez-Cubero MJ, De Miguel Pérez D, Rodríguez-Martínez A, Gonzalez-Herrera L, Robles-Fernández I, Hernandez JE, Puche JL and Lorente JA: Significance of EGF expression in circulating tumor cells. Adv Exp Med Biol 994: 285-296, 2017.

7. Schlessinger J: Ligand-induced, receptor-mediated dimerization and activation of EGFR receptor. Cell 110: 669-702, 2002.

8. Komposch K and Sibilia M: EGFr signaling in liver diseases. Int J Mol Sci 17: E30, 2015.

9. Zheng L, Liao D, Zhang M, Zeng C, Li X, Zhang R, Ma H and Kang F: YTHFD2 suppresses cell proliferation and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma. Cancer Lett 442: 252-261, 2019.

10. Zhu L, Liu R, Zhang W, Qian S and Wang J: Application of EGFR inhibitor reduces circulating tumor cells during transcutaneous arterial embolization. Clin Transl Oncol 20: 639-648, 2016.

11. Keating GM: Afatinib: a review in advanced non-small cell lung cancer. Target Oncol 11: 825-835, 2016.

12. Liu CY, Lin HH, Tang MJ and Wang YK: Vimentin contributes to epithelial-mesenchymal transition cancer stem cells: Therapeutic targets in hepatocellular carcinoma. J Hematol Oncol 9: 74, 2016.

13. Wang H, Wu Q, Zhang Y, Zhang HN, Wang YB and Wang W: TGF-β1-induced epithelial-mesenchymal transition in lung cancer cells involves upregulation of miR-9 and downregulation of its target, E-cadherin. Cell Mol Biol Lett 22: 22, 2017.

14. Liu CY, Lin HH, Tang MJ and Wang YK: Vimentin contributes to epithelial-mesenchymal transition cancer stem cells by mediating cytoskeletal organization and focal adhesion maturation. Oncotarget 6: 15966-15983, 2015.

15. Liu CY, Zeng L, Song H, Xiao J, Pan B, Chen H, Jin X and Yu H: Effects of microRNA-183 on epithelial-mesenchymal transition, proliferation, migration, invasion and apoptosis in human pancreatic cancer SW1900 cells by targeting MTA1. Exp Mol Pathol 102: 522-532, 2017.

16. Koyakisni R Jr: Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol Res 39: 345-351, 1998.

17. Ding D, Huang H, Jiang W, Yu W, Zhu H, Liu J, Saiyin H, Wu J, Huang J, Jiang S and Yu L: Reticulocbin-2 enhances hepatocellular carcinoma proliferation via modulating the EGFR-EKR pathway. Oncogene 36: 6691-6700, 2017.

18. Ye QH, Zhu WW, Zhang JB, Qin Y, Lu M, Lin GL, Guo L, Zhang B, Lin ZH, Roessler S, et al: GOLM1 modulates EGFR/RTK cell-surface recycling to drive hepatocellular carcinoma metastasis. Cancer Cell 30: 444-458, 2016.

19. Scintishi M and Basescu I: Epidermal growth factor receptor pathway: a model for targeted therapy. Cancer Clin Res 12: 5268-5272, 2016.

20. Ikeda S, Tsigelny IF, Skjevik AA, Kono Y, Mendler M, Kuo A, Sicklick JK, Heestand G, Banks KC, Talasz A, et al: Next-generation sequencing of circulating tumor DNA reveals frequent alterations in advanced hepatocellular carcinoma. Oncologist 23: 586-593, 2018.

21. Li R, Yanjiao G, Wubin H, Yue W, Jianhua H, Huachuan Z, Rongjian S and Zhidong L: Secreted GRP78 activates EGF-SCFR-STAT3 signaling and contributes the resistance to sorafenib in HCC cells. Oncotarget 8: 19354-19364, 2017.

22. Panvichian R, Tantiwetrueangdet A, Sornmayura P, Leelaadompli S: Missense mutations in exons 18-24 of EGFR in hepatocellular carcinoma tissues. Biomed Res Int 2015: 171845, 2015.
